Blandt patienter med plaque psoriasis behandlet i placebo- kontrollerede undersøgelser var hyppigheden af alvorlige bivirkninger ca.
In the second active-controlled trial the rate of serious adverse events after 2 years of treatment was similar among the three treatment groups (Enbrel 16%, methotrexate 15% and Enbrel in combination with methotrexate 17%).